(VIANEWS) - West Pharmaceutical (WST), Regeneron Pharmaceuticals (REGN), Stag Industrial (STAG) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. West Pharmaceutical (WST)
21.2% sales growth and 28.54% return on equity
West Pharmaceutical Services, Inc. manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, Ireland, France, Other European countries, and internationally.
West Pharmaceutical's sales growth this year is anticipated to be 30.4% and 8% for next year.
Year-on-year quarterly revenue growth grew by 37.3%, now sitting on 2.52B for the twelve trailing months.
Volume
Today's last reported volume for West Pharmaceutical is 315098 which is 23.66% below its average volume of 412775.
West Pharmaceutical's sales growth for the next quarter is 21.2%. The company's growth estimates for the current quarter and the next is 56.5% and 41.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 28.54%.
Volatility
West Pharmaceutical's last day, last week, and last month's current intraday variation average was 2.31%, 2.14%, and 1.30%, respectively.
West Pharmaceutical's highest amplitude of average volatility was 2.96% (day), 1.78% (last week), and 2.29% (last month), respectively.
West Pharmaceutical's Stock Yearly Top and Bottom Value
West Pharmaceutical's stock is valued at $399.55 at 05:22 EST, way below its 52-week high of $475.35 and way higher than its 52-week low of $253.85.
West Pharmaceutical's Moving Average
West Pharmaceutical's worth is under its 50-day moving average of $424.37 and above its 200-day moving average of $379.25.2. Regeneron Pharmaceuticals (REGN)
18.3% sales growth and 51.09% return on equity
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide.
Regeneron Pharmaceuticals's sales growth this year is expected to be 56.3% and a negative 10.8% for next year.
Year-on-year quarterly revenue growth grew by 50.5%, now sitting on 13.36B for the twelve trailing months.
Volume
Today's last reported volume for Regeneron Pharmaceuticals is 734979 which is 3.07% below its average volume of 758269.
Regeneron Pharmaceuticals's sales growth for the next quarter is 18.3%. The company's growth estimates for the present quarter and the next is 7.7% and 8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 51.09%.
Volatility
Regeneron Pharmaceuticals's last day, last week, and last month's current intraday variation average was 0.25%, 0.35%, and 1.00%, respectively.
Regeneron Pharmaceuticals's highest amplitude of average volatility was 2.60% (day), 1.73% (last week), and 2.47% (last month), respectively.
Regeneron Pharmaceuticals's Stock Yearly Top and Bottom Value
Regeneron Pharmaceuticals's stock is valued at $618.22 at 05:22 EST, under its 52-week high of $686.62 and way higher than its 52-week low of $441.00.
Regeneron Pharmaceuticals's Moving Average
Regeneron Pharmaceuticals's value is above its 50-day moving average of $610.79 and higher than its 200-day moving average of $567.66.3. Stag Industrial (STAG)
17.5% sales growth and 7.54% return on equity
STAG Industrial, Inc. (NYSE: STAG) is a real estate investment trust focused on the acquisition and operation of single-tenant, industrial properties throughout the United States.
Stag Industrial's sales growth this year is anticipated to be 15.8% and 13.9% for next year.
Year-on-year quarterly revenue growth grew by 21.2%, now sitting on 544.49M for the twelve trailing months.
Volume
Today's last reported volume for Stag Industrial is 304155 which is 74.52% below its average volume of 1194160.
Stag Industrial's sales growth for the next quarter is 17.5%. The company's growth estimates for the ongoing quarter and the next is a negative 76.2% and negative 0%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 7.54%.
Volatility
Stag Industrial's last day, last week, and last month's current intraday variation average was 1.31%, 1.27%, and 1.28%, respectively.
Stag Industrial's highest amplitude of average volatility was 1.40% (day), 1.76% (last week), and 2.45% (last month), respectively.
Stag Industrial's Stock Yearly Top and Bottom Value
Stag Industrial's stock is valued at $40.99 at 05:22 EST, way under its 52-week high of $48.27 and way higher than its 52-week low of $31.42.
Stag Industrial's Moving Average
Stag Industrial's value is below its 50-day moving average of $44.11 and below its 200-day moving average of $41.06.4. IDEX Corporation (IEX)
14% sales growth and 17.02% return on equity
IDEX Corporation, together with its subsidiaries, operates as an applied solutions company worldwide.
IDEX Corporation's sales growth this year is anticipated to be 16.1% and 7.5% for next year.
Year-on-year quarterly revenue growth grew by 22.2%, now sitting on 2.53B for the twelve trailing months.
Volume
Today's last reported volume for IDEX Corporation is 460634 which is 29.79% above its average volume of 354888.
IDEX Corporation's sales growth is a negative 0% for the current quarter and 14% for the next. The company's growth estimates for the ongoing quarter and the next is 14.3% and 18.2%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.02%.
Volatility
IDEX Corporation's last day, last week, and last month's current intraday variation average was 2.16%, 1.14%, and 1.42%, respectively.
IDEX Corporation's highest amplitude of average volatility was 3.10% (day), 2.00% (last week), and 2.75% (last month), respectively.
IDEX Corporation's Stock Yearly Top and Bottom Value
IDEX Corporation's stock is valued at $194.65 at 05:22 EST, way under its 52-week high of $236.67 and higher than its 52-week low of $185.23.
IDEX Corporation's Moving Average
IDEX Corporation's worth is way below its 50-day moving average of $218.54 and way below its 200-day moving average of $221.47.5. NeoGenomics (NEO)
10.1% sales growth and 5.42% return on equity
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia.
NeoGenomics's sales growth this year is expected to be 9.1% and 14.4% for next year.
Year-on-year quarterly revenue growth declined by 3.3%, now sitting on 484.59M for the twelve trailing months.
Volume
Today's last reported volume for NeoGenomics is 539794 which is 46.66% below its average volume of 1012000.
NeoGenomics's sales growth is a negative 0% for the present quarter and 10.1% for the next. The company's growth estimates for the current quarter and the next is a negative 200% and negative -275%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 5.42%.
Volatility
NeoGenomics's last day, last week, and last month's current intraday variation average was 3.18%, 2.24%, and 3.40%, respectively.
NeoGenomics's highest amplitude of average volatility was 9.24% (day), 7.97% (last week), and 6.57% (last month), respectively.
NeoGenomics's Stock Yearly Top and Bottom Value
NeoGenomics's stock is valued at $20.55 at 05:22 EST, way under its 52-week high of $61.57 and above its 52-week low of $20.42.
NeoGenomics's Moving Average
NeoGenomics's value is way under its 50-day moving average of $31.76 and way below its 200-day moving average of $41.57.6. MainStreet Bancshares (MNSB)
9.7% sales growth and 12.44% return on equity
MainStreet Bancshares, Inc. operates as the bank holding company for MainStreet Bank that provides various banking products and services for individuals, small to medium-sized businesses, and professional service organizations primarily in Northern Virginia and the greater Washington, the District of Columbia metropolitan area.
MainStreet Bancshares's sales growth this year is expected to be 7.8% and 10.6% for next year.
Year-on-year quarterly revenue growth declined by 15%, now sitting on 60.82M for the twelve trailing months.
Volume
Today's last reported volume for MainStreet Bancshares is 10996 which is 5.32% above its average volume of 10440.
MainStreet Bancshares's sales growth is a negative 0% for the current quarter and 9.7% for the next. The company's growth estimates for the ongoing quarter and the next is a negative 13.8% and negative -29.9%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.44%.
Volatility
MainStreet Bancshares's last day, last week, and last month's current intraday variation average was 1.05%, 0.95%, and 0.94%, respectively.
MainStreet Bancshares's highest amplitude of average volatility was 3.24% (day), 2.83% (last week), and 2.23% (last month), respectively.
MainStreet Bancshares's Stock Yearly Top and Bottom Value
MainStreet Bancshares's stock is valued at $24.70 at 05:22 EST, under its 52-week high of $26.85 and way above its 52-week low of $17.11.
MainStreet Bancshares's Moving Average
MainStreet Bancshares's value is above its 50-day moving average of $24.02 and above its 200-day moving average of $23.38.7. Zoetis (ZTS)
8% sales growth and 47.76% return on equity
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally.
Zoetis's sales growth this year is anticipated to be 15.1% and 8.3% for next year.
Year-on-year quarterly revenue growth grew by 11.4%, now sitting on 7.62B for the twelve trailing months.
Volume
Today's last reported volume for Zoetis is 2540730 which is 23.91% above its average volume of 2050380.
Zoetis's sales growth is a negative 0% for the ongoing quarter and 8% for the next. The company's growth estimates for the current quarter and the next is 0.9% and 11%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 47.76%.
Volatility
Zoetis's last day, last week, and last month's current intraday variation average was 1.46%, 0.88%, and 1.06%, respectively.
Zoetis's highest amplitude of average volatility was 2.39% (day), 2.09% (last week), and 2.22% (last month), respectively.
Zoetis's Stock Yearly Top and Bottom Value
Zoetis's stock is valued at $199.37 at 05:22 EST, way under its 52-week high of $231.91 and way above its 52-week low of $141.41.
Zoetis's Moving Average
Zoetis's worth is under its 50-day moving average of $213.52 and above its 200-day moving average of $190.29.8. Ameren (AEE)
5.9% sales growth and 10.4% return on equity
Ameren's sales growth this year is expected to be 6.1% and 4.4% for next year.
Year-on-year quarterly revenue growth grew by 5.5%, now sitting on 5.74B for the twelve trailing months.
Volume
Today's last reported volume for Ameren is 884699 which is 28.42% below its average volume of 1236080.
Ameren's sales growth for the next quarter is 5.9%. The company's growth estimates for the current quarter and the next is 8.8% and negative 0%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.4%.
Volatility
Ameren's last day, last week, and last month's current intraday variation average was 2.51%, 1.16%, and 1.05%, respectively.
Ameren's highest amplitude of average volatility was 2.40% (day), 1.53% (last week), and 1.74% (last month), respectively.
Ameren's Stock Yearly Top and Bottom Value
Ameren's stock is valued at $85.56 at 05:22 EST, below its 52-week high of $90.77 and way above its 52-week low of $69.79.
Ameren's Moving Average
Ameren's worth is above its 50-day moving average of $84.29 and higher than its 200-day moving average of $83.91.Previous days news about Ameren(AEE)
- According to Bloomberg Quint on Tuesday, 8 February, "Among the participants will be Southern Co. Chief Executive Officer Tom Fanning, American Electric Power Co Inc. Chief Executive Officer Nick Akins, Edison International Chief Executive Officer Pedro Pizarro, Ameren Corp. Executive Chairman Warner Baxter, Exelon Corp. Senior Vice President and Chief Operating Officer Calvin Butler, and DTE Energy Co. Chairman Gerry Anderson, company officials confirmed."